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Postpartum acute hemolytic transfusion 
reactions associated with anti-Lea in two 
pregnancies complicated by preeclampsia
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Case RepoRt
Lewis blood group antibodies, which are mostly naturally 
occurring and considered clinically insignificant, have rarely been 
documented as a cause of acute hemolytic transfusion reactions 
(AHTRs). This report presents two cases of AHTRs caused by 
anti-Lea occurring in postpartum black females (one group B, one 
group AB) whose pregnancies were complicated by preeclampsia. 
Neither anti-Lea was detected by automated solid-phase red cell 
adherence technology in pre-transfusion testing. Therefore, red 
blood cell units, compatible by electronic crossmatch, were issued 
and transfused. The subsequent transfusion reactions were 
characterized by acute intravascular hemolysis, evidenced by 
both clinical and laboratory criteria. These two cases demonstrate 
that, even when least anticipated, hemolytic transfusion reactions 
may occur. As expected, neither live-born neonate was affected 
by hemolytic disease of the fetus and newborn. Because both 
transfusion reactions occurred in non–group O, postpartum 
black females with pregnancies complicated by preeclampsia, 
possible links between in vivo hemolytic anti-Lea, non–group O 
pregnant black females, and preeclampsia may require additional 
investigation. Immunohematology 2017;33:114–118.
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Lewis blood group antibodies are very common in 
antenatal women and may be a result of the reduced Lewis 
antigen expression on the red blood cells (RBCs) that occurs 
during pregnancy.1 This decreased antigen expression of Lea 
and Leb, resulting in the Le(a–b–) phenotype, is thought to be 
caused by increased lipoprotein levels.2 The genetic Le(a–b–) 
phenotype is also much more common in black individuals.3 
Antibodies directed against Lea and Leb are mostly naturally 
occurring, usually of the IgM isotype, and typically clinically 
insignificant.3 Very few examples of acute hemolytic 
transfusion reactions (AHTRs) or delayed hemolytic 
transfusion reactions (DHTRs) caused by Lewis antibodies 
have been reported in the literature: a patient with chronic 
lymphocytic leukemia and anti-Lea,4 a patient with 
postpartum nephrectomy for a carcinoma and anti-Leb,5 a 
patient with ischemic colitis and diverticulitis and anti-LebH,6 
and a patient with sickle cell trait at 38 weeks of gestation 
with pyelonephritis and urosepsis and anti-Lea.7 There are no 
reported cases in recent literature of AHTRs caused by anti-
Lea occurring in preeclamptic women during the antepartum 
or postpartum period.
Preeclampsia is a pregnancy condition that presents 
with hypertension and proteinuria. Severe preeclampsia is 
characterized by systolic blood pressure (BP) of 160 mmHg, 
diastolic BP of 110 mmHg, proteinuria (>2 g/24 hours or 3+ 
proteinuria on a dipstick), and liver function tests that are two 
times the normal values.8 There are two types of preeclampsia: 
early-onset and late-onset. Most preeclampsia presents as 
late-onset (occurring after 34 weeks gestation9). Early-onset 
preeclampsia occurs at less than 33 weeks of gestation and has 
a higher mortality rate for both mother and neonate.9
Case Reports
The two patients presented in this report were both 
black females whose pregnancies were complicated by severe 
preeclampsia. One patient delivered at 37.1 weeks, and the 
other delivered at 28.7 weeks of gestation. Both patients 
had moderately severe, symptomatic, postpartum anemia 
requiring blood component support. Their antibody detection 
tests were negative, and they were therefore transfused with 
RBCs compatible by electronic crossmatch. Both patients 
suffered AHTRs as a result of anti-Lea. The possible roles of 
both preeclampsia and race should be considered in these two 
cases of AHTRs associated with an RBC alloantibody rarely 
considered clinically significant.
Patient 1
A pregnant 20-year-old black woman, gravida 2, para 1, 
with sickle cell trait, was admitted to the hospital with elevated 
BP requiring intravenous hypertensives. She was diagnosed 
with severe preeclampsia and anemia with a hemoglobin 
(Hb) of 6.6 g/dL (normal range 12.0 –16.0 g/dL). Labor was 
induced, and she delivered a live-born infant at 37.1 weeks 
of gestation. Pre-transfusion testing showed a blood type of 
group B, D+ and a negative antibody detection test by solid-
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phase red cell adherence (SPRCA). Four units of RBCs were 
selected for transfusion by electronic crossmatch. Post-delivery, 
her Hb was 6.4 g/dL, and 2 units of RBCs were transfused 
without incident. Transfusion of the third unit of RBCs was 
started, and the patient immediately experienced nausea 
and lower back pain. The transfusion was discontinued after 
20 mL was infused. The symptoms resolved within 3 hours 
without treatment. A transfusion reaction workup revealed 
no hemolysis and a negative direct antiglobulin test (DAT). 
No additional testing was performed. Approximately 4 hours 
later, a fourth unit of RBCs was started, and after 160 mL was 
infused, the patient experienced chills and a temperature rise 
from 98.9°F pre-transfusion to 100.2°F. Her pulse increased 
from 94 beats per minute (bpm) pre-transfusion to 109 bpm. 
The transfusion was discontinued. The post-transfusion 
sample showed hemolysis, a weakly positive DAT with anti-
C3b,-C3d only, and a negative antibody detection test by 
SPRCA. The urine was reported as tea-colored.
Patient 2
A pregnant 23-year-old black woman, gravida 1, para 1, 
had experienced seizures at home and was brought to another 
hospital with a BP of 169/69 mmHg (normal in pregnancy: 
<140/<90 mmHg). She was transferred and admitted to our 
hospital and diagnosed with eclampsia, hemolysis, elevated 
liver enzymes, and low platelet count (HELLP) syndrome, 
and severe thrombocytopenia. She underwent a caesarean 
section and delivered a live-born infant at 28 weeks, 5 days, 
of gestation. Pre-transfusion testing showed a blood type 
of group AB, D+ and a negative antibody detection test by 
SPRCA. Three units of apheresis platelets were transfused on 
the day of admission, and 2 units of platelets were transfused 3 
days postpartum. An antibody screen performed by SPRCA at 
3 days postpartum was negative. Four days post-delivery, the 
patient’s Hb had decreased from 10.8 g/dL pre-delivery to 6.9 
g/dL. One unit of RBCs, compatible by electronic crossmatch, 
was transfused. One hour after the transfusion was initiated, 
the patient experienced chills, rigors, tachypnea, tachycardia, 
and chest tightness. Her pulse increased from 113 bpm 
pre-transfusion to 140 to 150 bpm, and her BP increased 
from 140/84 mmHg pre-transfusion to 162/92 mmHg. The 
transfusion was discontinued. The patient was treated with 
acetaminophen and diphenhydramine, and her symptoms 
improved. A transfusion reaction workup revealed hemolysis 
in the post-transfusion sample.
Materials and Methods
RBC testing for ABO, Rh, and Lewis antigens was 
performed using reagents (Immucor, Norcross, GA) and 
supplies in accordance with manufacturers’ instructions 
and our standard operating procedures. Pre-transfusion 
automated antibody detection [Capture-R Ready-Screen (3); 
Immucor] was performed using an automated SPRCA assay 
platform (Galileo Echo; Immucor).
Post-transfusion reaction testing included the tube-
method DAT with Anti-IgG,-C3d; Polyspecific (Immucor), 
Anti-IgG (Immucor), and Anti-C3b,-C3d (Immucor). Serologic 
crossmatches, using patient plasma and donor RBCs, were 
performed using the tube method at immediate spin (IS), 
incubation at 37°C with a low-ionic-strength saline (LISS) 
(ImmuAdd; Immucor), and Anti-IgG in accordance with 
standard blood bank procedures.3 Antibody detection using 
Panoscreen I and II (Immucor) and antibody identification 
was performed using the traditional tube method3 with patient 
plasma and reagent RBCs at IS, 37°C/LISS, and anti-IgG anti-
human globulin (AHG) phases.
Results
Both patients had negative pre-transfusion antibody 
detection tests by the SPRCA assay so both were candidates 
for the electronic crossmatch. Both patients were transfused 
with electronically crossmatched RBCs, and both experienced 
an AHTR. Post-transfusion reaction testing revealed anti-Lea 
in pre-transfusion and post-transfusion samples from both 
patients. The anti-Lea was detected at IS, 37°C/LISS, and 
AHG phases of antibody detection and identification tests and 
crossmatches. 
Demographic, clinical, and serologic features of these two 
cases are summarized in Table 1.
Discussion
Antibodies to RBC antigens may be detected serologically, 
pre-transfusion or post-transfusion, by routine antibody 
detection methods, compatibility (crossmatch) testing, and 
DAT. Detection of antibodies is dependent on the different 
methods used in the blood bank such as gel, SPRCA, and tube 
testing using albumin, LISS, or polyethylene glycol (PEG).
A negative indirect antiglobulin test (IAT) for antibody 
detection and the use of electronic crossmatches for 
compatibility do not guarantee in vivo compatibility between 
patient plasma and donor RBCs, even if a patient has never 
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Table 1. Patient demographics and pre- and post-transfusion clinical and laboratory results
Index Patient 1 Patient 2




High BP (requiring IV antihypertensives)




Gestational age at delivery 37.1 weeks (labor induced) 28.7 weeks (elective caesarean section)
Gravid status Gravida 2, para 1 Gravida 1, para 1




ABO/D Group B, D+ Group AB, D+
Antibody detection test (SPRCA on 
Echo platform)
Negative Negative
Crossmatches (electronic) Compatible Compatible 
Transfusions
Day of delivery 2 RBCs (Units #1 and #2) 3 PLTs
PP Day 1 1 RBC (Unit #3)
PP Day 2 1 RBC (Unit #4)
PP Day 3 2 PLTs
PP Day 4 1 RBC (Unit #1)
Transfusion Reaction Symptoms RBC Unit #3 RBC Unit #4 RBC Unit #1
Symptoms Immediate nausea and back pain Chills and fever Chills, rigors, tachypnea
Tachycardia and chest tightness
Transfusion discontinued After infusion of 20 mL After infusion of 160 mL Within 1 hour 
Treatment Symptoms resolved without further 
treatment
NP Symptoms resolved with acetaminophen 
and diphenhydramine treatment 
Transfusion Reaction Workups RBC Unit #3 RBC Unit #4 RBC Unit #1
Patient plasma No hemolysis Visual hemolysis Visual hemolysis
Patient DAT Negative W+ with anti-C3b,-C3d Negative
Patient urine NP Tea-colored NP
Patient Ab detection test NP NP Negative by SPRCA
Laboratory testing NP NP Post-transfusion LDH peaked at 2031 IU/L 
from pre-transfusion of 573–1027 IU/L
Haptoglobin remained <30 mg/dL for 5 
days post-transfusion
Additional Testing/Findings Patient 1 Patient 2
Pre-transfusion sample(s)
Antibody identification Nonspecific cold agglutinin, IS only Anti-Lea identified at IS, 37°C, and AHG 
(anti-IgG) phases with all Le(a+b–) RBCs
Serologic XMs Incompatible at IS and 37°C/LISS
Negative at AHG (anti-IgG)
Incompatible at IS, 37°C, and AHG  
(anti-IgG)
Post-transfusion sample
Antibody identification Nonspecific cold agglutinin, IS only
Anti-Lea at 37°C/LISS [4 of 4 Le(a+) RBCs]
Anti-Lea at AHG (anti-IgG) [3 of 4 Le(a+) RBCs]
Anti-Lea identified at IS, 37°C, and AHG 
(anti-IgG) phases with all Le(a+b–) RBCs
Serologic XMs Incompatible at IS and 37°C/LISS
Negative at AHG (anti-IgG)
Incompatible at IS, 37°C, and AHG  
(anti-IgG)
RBC donor unit testing RBC Units #1 and #2 phenotyped as Le(a–b+)
RBC Units #3 and #4 phenotyped as Le(a+b–)
RBC Unit #1 phenotyped as Le(a+)
BP = blood pressure; IV = intravenous; HELLP = hemolysis, elevated liver enzymes, low platelets; Hb = hemoglobin; SPRCA = solid-phase red cell adherence; 
RBCs = red blood cells: PLTs = apheresis platelets; PP = postpartum; NP = not provided; DAT = direct antiglobulin test; Ab = antibody; LDH = lactate 
dehydrogenase; IS = immediate spin; XM = crossmatch; AHG = antihuman globulin; LISS = low-ionic-strength saline.
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been transfused. Naturally occurring antibodies, not detected 
in an IAT, can result in an AHTR.
Antibodies to Lewis blood group antigens are usually 
naturally occurring, cold-reacting, of the IgM isotype, and 
are considered clinically insignificant.3 Anti-Lea, however, is 
one of the few antibodies that is associated with intravascular 
hemolysis that occurs because of complement activation, 
usually associated with IgM-class antibodies.10 Common 
antibodies known to cause intravascular hemolysis are anti-A 
and anti-B, as well as anti-Jka, -Jkb, -Vel, -PP1Pk, -Lea,10 -IH, 
-Ge, -AnWj, and -Dia.8 Intravascular hemolysis can destroy 
approximately 1 unit of RBCs per hour, which can result in 
patient death.10
AHTRs caused by Lewis antibodies are extremely rare, 
and very few have been reported in the literature. In 2013, a 
patient with chronic lymphocytic leukemia was reported to 
have had an AHTR caused by anti-Lea that was reactive using 
direct agglutination at a “strictly controlled temperature of 
37°C.” Pre-transfusion testing had shown a negative antibody 
detection test and crossmatch, both with gel (37°C/IAT).4 
In 2015, an AHTR was reported due to anti-Leb in a group 
B, D+ postpartum black woman with no previous history of 
transfusion who underwent a nephrectomy for a carcinoma. 
This patient’s plasma reacted with the B reagent RBCs in 
the reverse type. This antibody was considered to be a cold 
antibody. The antibody detection test using SPRCA was 
negative, and electronic crossmatches were performed. Anti-
Leb was identified in the pre-transfusion and post-transfusion 
reaction samples. An immunohematology reference laboratory 
confirmed that the anti-Leb reacted in all phases by LISS and 
PEG, and in the AHG phase using the gel method.5 In 1987, 
a DHTR, as a result of anti-LebH, was reported. In this case, 
the first DHTR occurred 12 days post-transfusion but was not 
reported to the blood bank. A few days later, pre-transfusion 
testing revealed anti-LebH, anti-E, and a possible anti-K. The 
patient was transfused with E–, K–, crossmatch-compatible 
RBCs that were not tested for Lewis antigens. After transfusion 
with a Le(b+) unit of RBCs that was E–, K–, the patient had 
severe, immediate hemolysis.6
The cases reported here showed intravascular hemolytic 
transfusion reactions due to anti-Lea after negative pre-
transfusion antibody detection tests by SPRCA and 
compatible blood by electronic crossmatch only. The pre-
transfusion and post-transfusion reaction samples for both 
patients using the tube method demonstrated incompatible 
serologic crossmatches at immediate spin and 37°C/LISS. The 
crossmatch for Patient 2 was also incompatible at the AHG 
phase with both the pre-transfusion and post-transfusion 
reaction samples by tube method.
Both neonates were unaffected. They were not anemic, 
and both had Hb levels greater than or equal to 16 g/dL 
(normal 13.5–19.5 g/dL) at birth. One neonate (Patient 2) was 
diagnosed with neonatal jaundice associated with preterm 
delivery. This neonate’s total bilirubin was 3.5 mg/dL (normal 
<11.6 mg/dL) at birth. The other neonate (Patient 1) had a 
total bilirubin of 5.2 mg/dL on the second day of life. DATs 
were not performed. Because cord RBCs are not agglutinated 
by anti-Lea or anti-Leb,11 neonates are considered Le(a–b–). A 
study of seven perinatal women with Lewis antibodies showed 
no evidence of hemolytic disease of the fetus and newborn.12 
This finding was attributed to lack of Lewis antigen on the 
neonates’ RBCs and the fact that Lewis antibodies are of the 
IgM isotype, which does not cross the placenta.
In general, transfusion services attempt to avoid detecting 
naturally occurring, non–clinically significant, IgM antibodies, 
reacting in vitro at temperatures below 37°C. In vitro antibody 
reactivity at 37°C or at the AHG phase of testing usually is an 
indication of clinical significance.13 Lewis antibodies, except 
in rare instances, belong in the category of non–clinically 
significant, naturally occurring antibodies and are usually 
of the IgM isotype, although an IgG component may be 
present.13 The antibodies in the Lewis system usually react 
at temperatures less than 37°C. Without gentle resuspension, 
fragile agglutination at 37°C may be easily dispersed.3 RBCs 
that are crossmatch-compatible at 37°C are not expected to 
have decreased survival in vivo.3 Many transfusion services 
routinely eliminate the room temperature phase of the IAT 
for antibody detection to avoid interference with cold-reacting 
antibodies having specificities to M, N, P1, and Lewis antigens.
The Le(a–b–) phenotype is more common in black 
individuals (25% in blacks versus 8% in whites).11 In addition, 
pregnant women often lose their normally expressed Lewis 
antigens and develop naturally occurring antibodies to Lewis 
antigens, resulting in a temporary Le(a–b–) phenotype.14 A 
study in 1970 showed that about 70.4 percent of individuals 
with Lewis antibodies are pregnant women.1 They also 
concluded that group O individuals tend to have Lewis 
antibodies less often than group A individuals, which the 
authors stated was a “well-known fact.” The two index patients 
presented in this report were both non–group O, being group 
B, D+ and group AB, D+.
Adverse transfusion reactions can occur even in patients 
not previously transfused.15 Hemolytic transfusion reactions 
(HTRs) can be caused by RBC alloantibodies that are immune, 
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naturally occurring, or passively acquired.16 AHTRs can occur 
even when least expected. They can be immediate, within the 
first minutes of the blood unit infusion, or they can occur up 
to a few hours after the transfusion has been completed.8 Most 
AHTRs are expected to occur with ABO mismatches, but 
HTRs associated with Lewis, IH, Ge, AnWj, and Dia antibodies 
have been reported.8 It is important that transfusionists 
closely monitor patients during transfusions, adhering to the 
required standards of practice. Baseline vital signs should be 
taken and documented prior to transfusion. The patient should 
be observed for at least the first 15 minutes of the infusion, 
with vital signs monitored periodically throughout and at 
completion of the transfusion.8 In addition to changes in vital 
signs, transfused patients need to be observed for other signs 
of transfusion reaction, including any type of pain, chills/
rigors, nausea, and respiratory distress.8 Specific symptoms of 
an AHTR may be any of the following: chest pain, abdomen 
or back pain, nausea, vomiting, headache, chills, fever, 
hematuria, tachycardia, hypotension, and dyspnea.17 Patients 
who are awake and alert should be engaged in reporting signs 
and symptoms themselves. The blood bank technologist 
should also be cognizant of serologic evidence of HTR, such 
as unexpected reactivity in antibody detection testing or an 
incompatible crossmatch with a post-transfusion sample, 
since clinical symptoms are often unnoticed or unreported. 
Laboratory evidence of HTR may be free hemoglobin in the 
plasma and urine, decreased haptoglobin, increased indirect 
bilirubin, increased lactate dehydrogenase, and icterus.17
Common blood bank practice is to avoid detection of 
clinically insignificant RBC alloantibodies, which are mostly 
of the IgM isotype. The SPRCA assay may decrease detection 
of these unwanted antibodies because it uses IgG-coated 
indicator cells, which only detect IgG antibodies,11 avoiding the 
detection of IgM antibodies. When using SPRCA, the presence 
of IgG antibody in the tested plasma is required to detect Lewis 
antibodies as well as antibodies to the antigens, P1, M, or N.18 
Antibodies of the IgM isotype, however, although considered 
non–clinically significant, can cause HTRs. Detection of a 
clearly significant anti-Lea that reacted at IS and 37°C was 
missed in both patients reported here. Although extremely 
unusual and rarely reported in the literature, AHTRs do occur 
due to Lewis antibodies. This finding is evidenced by the two 
cases presented in this report of black, pregnant, preeclamptic 
females whose postpartum courses were complicated by 
AHTRs due to anti-Lea. The relationships between race, 
pregnancies complicated by preeclampsia, and clinically 
significant Lewis antibodies in non–group O individuals are 
unclear and warrant further study.
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